🟧 25th Annual Needham Virtual Healthcare Conference: Definium Therapeutics 🟧

Definium Therapeutics discusses its clinical progress in developing a proprietary form of LSD for GAD (generalized anxiety disorder) and MDD (major depressive disorder). The discussion centers on the company's clinical trial designs, specifically the Emergent study and the Voyage study. The speakers highlight the strategic use of double-blind, trigger-based dosing protocols which include open-label treatment extensions. These designs prioritize the collection of meaningful efficacy data and provide a robust framework for assessing potential treatment outcomes compared to placebo. Furthermore, the interview touches on the commercial and clinical implications of targeting these conditions. By setting high standards for clinical rigor in trial design, the company aims to establish a clear development pathway. The speakers emphasize that focus on patient-centered outcomes, rather than just symptom reduction, is crucial to their approach.